Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
Follow CLLS
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
166.85 | 185.66 | 208.66 | 192.22 |
+8 more quarters Free account |
Receivables |
12.60 | 12.75 | 22.20 | 24.47 | |
Other current assets |
4.97 | 6.14 | 5.38 | 4.50 | |
Total current assets |
184.42 | 204.55 | 236.24 | 221.19 | |
Property, Plant, Equpment (Net) |
34.80 | 37.40 | 38.79 | 41.20 | |
Long-Term Investments |
4.72 | 4.82 | 5.09 | 35.74 | |
Goodwill and Intangible Assets (Total) |
1.12 | 0.22 | 0.54 | 0.85 | |
Long Term Assets (Tax, Deferred) |
0.38 | 0.38 | 0.38 | 0.38 | |
Long-term assets (Other) |
22.73 | 21.29 | 20.03 | 18.18 | |
Total non-current assets |
82.95 | 84.64 | 88.48 | 121.85 | |
Total Assets |
267.37 | 289.19 | 324.72 | 343.05 | |
Accounts Payable |
18.20 | 17.09 | 17.28 | 16.10 | |
Current Part of Debt |
7.50 | 8.90 | 10.46 | 18.24 | |
Current Revenue (Deferred) |
90.92 | 93.06 | 96.80 | 94.01 | |
Other current liabilities |
11.56 | 9.19 | 13.51 | 11.90 | |
Total current liabilities |
134.96 | 134.50 | 145.75 | 148.58 | |
Long Term Debt (Total) |
66.19 | 67.50 | 74.01 | 63.40 | |
Non-current Liabilities (Other) |
1.33 | 1.32 | 1.33 | 1.34 | |
Total non-current liabilities |
91.34 | 94.77 | 103.07 | 93.99 | |
Total liabilities |
226.30 | 229.27 | 248.82 | 242.57 | |
Additional Paid In Capital |
371.75 | 439.14 | 437.45 | 435.16 | |
Common Stock (Net) |
5.92 | 5.92 | 5.90 | 5.90 | |
Retained Earnings |
(303.93) | (351.94) | (334.13) | (307.86) | |
Shareholders Equity (Other) |
(32.68) | (33.20) | (33.32) | (32.72) | |
Common Equity (Total) |
41.07 | 59.92 | 75.90 | 100.48 | |
Shareholders Equity (Total) |
41.07 | 59.92 | 75.90 | 100.48 | |
Shareholders Equity and Liabilities (Total) |
267.37 | 289.19 | 324.72 | 343.05 | |
Shares (Common) |
72.70 | 72.60 | 72.34 | 72.33 | |
Shareholders Equity (Tangible) |
39.95 | 59.70 | 75.37 | 99.63 | |
Net Debt |
(93.16) | (109.26) | (124.19) | (110.58) | |
Total Debt |
73.69 | 76.40 | 84.47 | 81.64 |